x

Posted 16 January, 2024

Adhera Therapeutics, Inc. appointed new CEO

CEO Change detected for ticker OTC:ATRX in a 8-K filed on 16 January, 2024.


  Further, on January 12, 2024, the Company received notice from Zahed Subhan that he was resigning as the Company's Chief Executive Officer and as a member of the Company's Board of Directors.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Adhera Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Adhera Therapeutics, Inc. is an emerging specialty biotech company, which is in the process of evaluating its focus including a return to drug discovery and development. The company was founded on September 23, 1983 and is headquartered in Baton Rouge, LA.
Market Cap
$103K
View Company Details
Adhera Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On January 9, 2024, Adhera Therapeutics, Inc. (the "Company") received notice from Trond K. Waerness that he was resigning from the Company's Board of Directors effective January 12, 2024. Mr. Waerness' decision to resign as director was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.


Further, on January 12, 2024, the Company received notice from Zahed Subhan that he was resigning as the Company's Chief Executive Officer and as a member of the Company's Board of Directors. Mr. Subhan's decision to resign as Chief Executive Officer and member of the Company's Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.